Contraception and Reproductive Medicine (Feb 2024)

Comparison of luteal phase stimulation with follicular phase stimulation in poor ovarian response: a single-blinded randomized controlled trial

  • Mozhgan Vahabi Dastjerdi,
  • Soheila Ansaripour,
  • Mina Ataei,
  • Roya Gharedaghi,
  • Seyedeh Melika Mostafavi Hoseini,
  • Arash Mohazzab,
  • Simin Zafardoust

DOI
https://doi.org/10.1186/s40834-024-00265-z
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background In the last decade, luteal-phase ovarian stimulation (LPOS) has been suggested as an alternative controlled ovarian stimulation (COS) protocol for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles mainly in women with a history of poor ovarian response (POR). The present randomized controlled trial study aimed to compare the outcomes of follicular phase ovarian stimulation (FPOS) and LPOS protocols in POR cases undergoing ICSI cycles. Methods Seventy-eight POR patients who met the Bologna criteria and underwent an ICSI cycle were included. In this study, 39 POR cases were allocated to the FPOS group, and 39 POR cases were allocated to the LPOS group. The primary outcome was the number of metaphase II (MII) oocytes. In addition, the total number of oocytes, number of top-quality day 3 embryo, day 3 embryo development rate, chemical pregnancy and clinical pregnancy rates were defined as secondary outcomes. Results The obtained results demonstrated that the number of MII oocytes significantly increased in the LPOS group compared to the FPOS group (P = 0.007). However, there was no significant difference between the two groups regarding the number of GV and MI oocytes, number of top-quality day 3 embryos and day 3 embryo development rate among both categories of patients. Also, the number of total and MII oocytes was significantly higher in the LPOS group (P = 0.016). Conclusion These results suggest that LPOS protocol effectively increases the number of mature oocytes in women with a history of POR. Trial registration IRCT20210405050852N1 (Registered at Iranian registry of clinical trials; available at https://en.irct.ir/trial/55402 ).

Keywords